Core Viewpoint - 康泰生物 has decided to terminate its collaboration with AstraZeneca Investment (China) Co., Ltd. for establishing a joint venture in the vaccine sector, stating that this termination will not have a significant adverse impact on the company [1]. Group 1: Joint Venture Details - The collaboration plan between 康泰生物 and AstraZeneca began in March 2025, with the intention to set up a joint venture in the Beijing Economic and Technological Development Area, focusing on vaccine business [1]. - The registered capital for the joint venture was expected to be 345 million yuan (approximately 50 million USD), with both parties holding a 50% stake, and a total investment of around 400 million USD (approximately 2.76 billion yuan) [1]. - As of the announcement, the joint venture had not yet been established, and 康泰生物 had not made any actual contributions [1]. Group 2: Reasons for Termination - 康泰生物 cited significant changes in the market environment and considerable downward pressure on the vaccine industry as reasons for the termination [1]. - The company assessed that the risks associated with new vaccine industry investments were high, leading to the mutual decision to terminate the cooperation agreement and the establishment of the joint venture [1]. - Following the termination, neither party will bear any further obligations or responsibilities related to the agreement [1].

Core Viewpoint - The company announced the termination of the investment agreement to establish a joint venture with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Joint Venture Details - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] Group 2: Termination of Agreement - The decision to terminate the investment agreement was made after careful evaluation and friendly negotiations among the parties involved [1] - The termination was approved in a board meeting held on February 6, 2026, and the company management was authorized to finalize and sign the relevant termination agreements [1]

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has decided to terminate its plan to establish a joint venture with AstraZeneca Investment (China) Co., Ltd. due to significant changes in the market environment and increased investment risks in the vaccine industry [1] Group 1: Joint Venture Details - The joint venture was initially planned to be established in March 2025, with both companies holding a 50% stake and a registered capital of approximately 345 million RMB, with a total investment of around 400 million USD [1] - The decision to terminate the joint venture was made after careful evaluation and friendly consultation among the parties involved, as the new vaccine industry investment risks were deemed too high [1] Group 2: Impact on Company Operations - As of now, the joint venture has not been established, and Kangtai Biological has not made any actual capital contributions [1] - The company stated that this termination will not have a significant impact on its existing business, financial status, or operational conditions [1] - Kangtai Biological will continue to pursue its strategy of "internal innovation + external expansion" and deepen its international business layout [1]